Determine the necessary mass, volume, or concentration for preparing a solution.
This is a demo store. No orders will be fulfilled.
| SKU | Size | Availability |
Price | Qty |
|---|---|---|---|---|
|
Ab183329-100μg
|
100μg |
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
|
$189.90
|
|
|
Ab183329-1mg
|
1mg |
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
|
$919.90
|
|
|
Ab183329-5mg
|
5mg |
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
|
$2,299.90
|
|
|
Ab183329-10mg
|
10mg |
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
|
$3,679.90
|
|
Purity>90% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG1; CHO; ELISA, FACS, Functional assay, Animal Model; Conjugated (MC-VC-PAB-MMAE)
| Product Name | Ladiratuzumab vedotin (anti-SLC39A6) - Primary antibody, specific to SLC39A6, >90% (SDS-PAGE&SEC), high purity, Human IgG1, INHIBITOR of Tubulin inhibitor |
|---|---|
| Synonyms | Estrogen regulated protein LIV 1 6 antibody | Estrogen-regulated protein LIV-1 antibody | LIV 1 antibody | LIV 1 protein, estrogen regulated antibody | S39A6_HUMAN antibody | SLC39A6 antibody | Solute carrier family 39 (metal ion transporter), member 6 an |
| Specifications & Purity | Carrier Free, Recombinant, ExactAb™, Low Endotoxin, Azide Free, Validated, Animal Free, ≥90%(SDS-PAGE&SEC-HPLC), See COA |
| Host species | Human |
| Specificity | SLC39A6 |
| Conjugation | MC-VC-PAB-MMAE |
| Grade | Animal Free, Azide Free, Carrier Free, ExactAb™, Low Endotoxin, Recombinant, Validated |
| Action Type | INHIBITOR |
| Mechanism of action | INHIBITOR of Tubulin inhibitor |
| Product Description |
Ladiratuzumab vedotin (anti-SLC39A6) is an antibody-drug conjugate (ADC) composed of humanized anti-LIV-1 antibody, conjugated to Monomethyl auristatin E (MMAE), via a proteolytically cleavable type linker. Ladiratuzumab vedotin (anti-SLC39A6) has the potential for use in multiple carcinomas. |
| Isotype | Human IgG1 |
|---|---|
| Light Chain Type | kappa |
| SDS-PAGE | 146.96 kDa |
| Purification Method | Protein A purified |
| Purity | >90% (SDS-PAGE&SEC) |
| Shape | Liquid |
| Concentration | See COA |
| Storage Temp | Store at -80°C,Avoid repeated freezing and thawing |
| Shipped In | Ice chest + Ice pads |
| Stability And Storage | Store at -80℃ for 24 months. Upon receipt, it is recommended to aliquot. Avoid freeze/thaw cycle. |
| CAS | 1629760-29-7 |
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
Ladiratuzumab vedotin (anti-SLC39A6) (Ab183329) - Flow Cytometry
Flow Cytometry analysis of Jurkat cells labelling SLC39A6 (red) with Ladiratuzumab vedotin (anti-SLC39A6) (Ab183329) at 1.0 μg/mL for 1 hour at 4°C. Goat Anti-Human IgG (PE) (Ab175838) at a dilution of 1/1000 was used as the secondary antibody. Blue - Isotype control, human IgG (Ab170213). Black - Unlabelled control, cells without incubation with primary antibody.
Ladiratuzumab vedotin (anti-SLC39A6) (Ab183329) - Flow Cytometry
Flow Cytometry analysis of ZDFH001-human-LIV1 A6-C2203027 cells at 1×105 cell/well can bind Ladiratuzumab vedotin (anti-SLC39A6) (Ab183329) with the EC₅₀ of 80.0 ng/mL.
Ladiratuzumab vedotin (anti-SLC39A6) (Ab183329) - SEC
The purity of Ladiratuzumab vedotin (anti-SLC39A6) (Ab183329) is more than 95% verified by HPLC.
Ladiratuzumab vedotin (anti-SLC39A6) (Ab183329) - ELISA
Immobilized Recombinant Human SLC39A6/LIV-1 Protein (rp176717) at 1.0 μg/mL can bind Ladiratuzumab vedotin (anti-SLC39A6) (Ab183329) with the EC₅₀ of 18.4 ng/mL.